Fenfluramine Hydrochloride Patent Expiration
Fenfluramine Hydrochloride is used for reducing or ameliorating seizures in patients with Dravet or Lennox-Gastaut syndrome through various combination therapies and cardiac monitoring to mitigate cardiovascular risk. It was first introduced by Ucb Inc
Fenfluramine Hydrochloride Patents
Given below is the list of patents protecting Fenfluramine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fintepla |
US10452815 (Pediatric) | Control system for control of distribution of medication | Dec 29, 2038 | Ucb Inc |
| Fintepla | US10452815 | Control system for control of distribution of medication | Jun 29, 2038 | Ucb Inc |
| Fintepla |
US10603290 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11040018 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11406606 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11759440 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11786487 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla | US10603290 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11040018 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11406606 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11759440 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11786487 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla |
US10947183 (Pediatric) | Fenfluramine compositions and methods of preparing the same | Jun 20, 2037 | Ucb Inc |
| Fintepla | US10947183 | Fenfluramine compositions and methods of preparing the same | Dec 20, 2036 | Ucb Inc |
| Fintepla |
US10950331 (Pediatric) | Control system for control of distribution of medication | Mar 28, 2036 | Ucb Inc |
| Fintepla | US10950331 | Control system for control of distribution of medication | Sep 28, 2035 | Ucb Inc |
| Fintepla |
US10478441 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US10478442 (Pediatric) | Method for the treatment of Dravet Syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9549909 (Pediatric) | Method for the treatment of dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9603814 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9603815 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9610260 (Pediatric) | Method for the treatment of Dravet Syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla | US10478441 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US10478442 | Method for the treatment of Dravet Syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9549909 | Method for the treatment of dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9603814 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9603815 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9610260 | Method for the treatment of Dravet Syndrome | May 03, 2033 | Ucb Inc |
Fenfluramine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List